![]() ![]() This article appeared in print in the January 6th, 2015 edition of Hamodia. ![]() Arie Belldegrun, Kite Pharma’s chief executive, said in a statement. “Amgen is an ideal partner for us based on their strong presence in oncology,” Dr. Anonymous discussion boards for pharma/medical companies that no longer exist due to acquisition or other factors. JanuAmgen and Kite Pharma to develop CAR T cell immunotherapies US-based Amgen has signed a strategic research collaboration and license agreement with Kite Pharma to develop and commercialise chimeric antigen receptor (CAR) T cell immunotherapies. Anonymous discussion boards for pharmaceutical and biotech companies. Under the terms of the agreement, Amgen will contribute cancer targets while Kite will offer up its CAR drug discovery platform, R&D and manufacturing capabilities, as well as its. Kite’s stock has rallied significantly since going public in June at $17 a share. Discussion boards of general interest for those in the pharma, biotech, medical device, and related industries. US biotech firm Amgen and early cancer drug discovery company Kite Pharma have signed a major research and development deal focused on therapeutic oncology vaccines. Further terms of the agreement weren’t disclosed. Kite can also receive up to $525 million in milestone payments.Īmgen is also eligible to receive up to $525 million in milestone payments as part of the collaboration, the companies said. The partnership announced Monday focuses on immunotherapy drugs that are intended to stimulate the body’s immune system to attack cancer cells.Īmgen said it will pay Kite $60 million upfront. Amgen, based in Thousand Oaks, Calif., saw its shares fall $1.90, or 1.2 percent, to $157.99. Shares of Kite Pharma rose $9.14, or 15.1 percent, to $69.75 in trading Monday. to develop cancer treatments, a deal that sent Kite’s stock soaring. is teaming up with biotech giant Amgen Inc. Santa Monica, Calif.-based Kite Pharma Inc. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |